Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells

Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells
复制标题

DOI:
10.1084/jem.20191290
复制
发表时间:
2020-04-01
影响因子:
15.3
通讯作者:
Shibuya, Kazuko
Shibuya, Kazuko
中科院分区:
医学1区
文献类型:
--
作者:
Okumura, Genki;Iguchi-Manaka, Akiko;Shibuya, Kazuko

文献摘要

被引文献

相似文献

CD155 是 DNAM-1、TIGIT 和 CD96 的配体,参与肿瘤免疫反应。与小鼠细胞不同,人类细胞表达膜 CD155 和由 CD155 剪接亚型编码的可溶性 CD155 (sCD155)。然而,sCD155在肿瘤免疫中的作用仍不清楚。在这里,我们发现,静脉注射产生 sCD155 的 B16/BL6 黑色素瘤后,野生型 (WT)、TIGIT 敲除 (K0) 或 CD96 KO 小鼠(而非 DNAM-1 KO 小鼠)中的肿瘤集落数量大于注射亲本 B16/BL6 黑色素瘤后的肿瘤集落数量。 NK 细胞耗竭消除了 WT 小鼠肿瘤集落数量的差异。体外测定表明 sCD155 干扰 DNAM-1 介导的 NK 细胞脱颗粒。此外,DNAM-1对sCD155的亲和力比TIGIT和CD96更大,表明sCD155优先与DNAM-1结合。总之,这些结果表明 sCD155 抑制 DNAM-1 介导的 NK 细胞的细胞毒活性,从而促进 B16/BL6 黑色素瘤的肺部定植。
CD155 is a ligand for DNAM-1, TIGIT, and CD96 and is involved in tumor immune responses. Unlike mouse cells, human cells express both membranous CD155 and soluble CD155 (sCD155) encoded by splicing isoforms of CD155. However, the role of sCD155 in tumor immunity remains unclear. Here, we show that, after intravenous injection with sCD155-producing B16/BL6 melanoma, the numbers of tumor colonies in wild-type (WT), TIGIT knock-out (K0), or CD96 KO mice, but not DNAM-1 KO mice, were greater than after injection with parental B16/BL6 melanoma. NK cell depletion canceled the difference in the numbers of tumor colonies in WT mice. In vitro assays showed that sCD155 interfered with DNAM-1-mediated NK cell degranulation. In addition, DNAM-1 had greater affinity than TIGIT and CD96 for sCD155, suggesting that sCD155 bound preferentially to DNAM-1. Together, these results demonstrate that sCD155 inhibits DNAM-1-mediated cytotoxic activity of NK cells, thus promoting the lung colonization of B16/BL6 melanoma.